Xtl Biopharmaceuticals (XTLB) Income from Continuing Operations (2009 - 2024)
Xtl Biopharmaceuticals (XTLB) posted quarterly Income from Continuing Operations of 448000.0 for Q4 2024, up 133.68% year-on-year from 191711.71 in Q1 2024, and down 78.14% on a QoQ basis from 2049000.0 in Q3 2024.
Xtl Biopharmaceuticals (XTLB) Income from Continuing Operations (2009 - 2024) Analysis & Trends
Xtl Biopharmaceuticals (XTLB) has reported Income from Continuing Operations for 16 consecutive years, with 448000.0 the latest figure, recorded in Q4 2024.
- Quarterly Income from Continuing Operations rose 133.68% year-over-year to 448000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 2278000.0 (up 241.84% YoY) and the FY2025 annual result came in at 759000.0, down 231.31% from the prior year.
- Income from Continuing Operations declined to 448000.0 in Q4 2024 per XTLB's latest filing, from 2049000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for XTLB reached as high as 2049000.0 in Q3 2024 and fell as low as 1776000.0 in Q4 2021.
- A 5-year average of 52452.3 and a median of 217000.0 in 2020 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2021 — Income from Continuing Operations jumped 689.86% — and 2023, when it sank 281.62%.
- Year by year, Income from Continuing Operations stood at 1875046.0 in 2020, then sank by 194.72% to 1776000.0 in 2021, then rose by 13.57% to 1535000.0 in 2022, then gained by 13.36% to 1330000.0 in 2023, then soared by 133.68% to 448000.0 in 2024.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 448000.0, 2049000.0, and 704000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Xtl Biopharmaceuticals | 2.60 Bn | 2.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 448,000.00 |
| Sep 30, 2024 | 2.05 Mn |
| Jun 30, 2024 | -704,000.00 |
| Mar 31, 2024 | 485,000.00 |
| Dec 31, 2023 | -1.33 Mn |
| Sep 30, 2023 | 1.01 Mn |
| Jun 30, 2023 | -364,000.00 |
| Mar 31, 2023 | -919,000.00 |
| Dec 31, 2022 | -1.54 Mn |
| Sep 30, 2022 | 1.11 Mn |
| Jun 30, 2022 | -285,000.00 |
| Mar 31, 2022 | 506,000.00 |
| Dec 31, 2021 | -1.78 Mn |
| Sep 30, 2021 | 1.28 Mn |
| Jun 30, 2021 | -303,000.00 |
| Mar 31, 2021 | -232,000.00 |
| Dec 31, 2020 | 1.88 Mn |
| Sep 30, 2020 | -217,000.00 |
| Jun 30, 2020 | -217,000.00 |
| Mar 31, 2020 | 173,000.00 |